SFA — Sopharma AD Income Statement
0.000.00%
- BGN1.33bn
- BGN1.74bn
- BGN2.15bn
- 45
- 51
- 90
- 71
Annual income statement for Sopharma AD, fiscal year end - December 31st, BGN millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1,450 | 1,616 | 1,675 | 1,895 | 2,153 |
| Cost of Revenue | |||||
| Gross Profit | 270 | 311 | 324 | 377 | 420 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 1,412 | 1,564 | 1,609 | 1,800 | 2,072 |
| Operating Profit | 38.5 | 51.6 | 66.3 | 94.8 | 80.9 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 31.4 | 97.6 | 85.1 | 111 | 92.1 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 25.3 | 91.7 | 76.3 | 99.9 | 80.4 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 29.8 | 89.5 | 71.1 | 96 | 76.3 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 29.8 | 89.5 | 71.1 | 96 | 76.3 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.1 | 0.184 | 0.253 | 0.25 | 0.159 |
| Dividends per Share |